GPhA Talking To CMS About Medicaid "Best Price" For "Authorized" Generics

Federal and state governments are losing "substantial dollars" because innovators are not including authorized generics in their best price calculations for brand drugs, GPhA CEO Jaeger says. The group is highlighting the "inconsistency" in how FDA and the Centers for Medicare & Medicaid Services treat authorized generics.